One of this year’s biggest loss-of-exclusivity opportunities for the US off-patent industry has come to pass, after the US Food and Drug Administration approved more than a dozen generic rivals to Takeda’s blockbuster attention-deficit/hyperactivity disorder treatment Vyvanse (lisdexamfetamine).
Generic versions of lisdexamfetamine capsules in 10mg, 20mg, 30mg 40mg, 50mg, 60mg and 70mg strengths have been approved by the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?